FR3076711B1 - Composition comprenant l'hydroxychloroquine et utilisation therapeutique - Google Patents

Composition comprenant l'hydroxychloroquine et utilisation therapeutique Download PDF

Info

Publication number
FR3076711B1
FR3076711B1 FR1800052A FR1800052A FR3076711B1 FR 3076711 B1 FR3076711 B1 FR 3076711B1 FR 1800052 A FR1800052 A FR 1800052A FR 1800052 A FR1800052 A FR 1800052A FR 3076711 B1 FR3076711 B1 FR 3076711B1
Authority
FR
France
Prior art keywords
composition including
therapeutic use
hydroxychloroquine
including hydroxychloroquine
triple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1800052A
Other languages
English (en)
Other versions
FR3076711A1 (fr
Inventor
Pierre Eftekhari
Rachel Amouroux
Angelique Quartier
Jean-Christophe Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOVIEM SCIENT
Original Assignee
INOVIEM SCIENT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOVIEM SCIENT filed Critical INOVIEM SCIENT
Priority to FR1800052A priority Critical patent/FR3076711B1/fr
Priority to PCT/FR2019/050081 priority patent/WO2019138203A1/fr
Publication of FR3076711A1 publication Critical patent/FR3076711A1/fr
Application granted granted Critical
Publication of FR3076711B1 publication Critical patent/FR3076711B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des compositions comprenant l'hydroxychloroquine pour son utilisation dans la prévention et/ou le traitement du cancer du sein triple-négatif.
FR1800052A 2018-01-15 2018-01-15 Composition comprenant l'hydroxychloroquine et utilisation therapeutique Active FR3076711B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1800052A FR3076711B1 (fr) 2018-01-15 2018-01-15 Composition comprenant l'hydroxychloroquine et utilisation therapeutique
PCT/FR2019/050081 WO2019138203A1 (fr) 2018-01-15 2019-01-15 Composition comprenant l'hydroxychloroquine et utilisation therapeutique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1800052 2018-01-15
FR1800052A FR3076711B1 (fr) 2018-01-15 2018-01-15 Composition comprenant l'hydroxychloroquine et utilisation therapeutique

Publications (2)

Publication Number Publication Date
FR3076711A1 FR3076711A1 (fr) 2019-07-19
FR3076711B1 true FR3076711B1 (fr) 2020-10-30

Family

ID=62143312

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1800052A Active FR3076711B1 (fr) 2018-01-15 2018-01-15 Composition comprenant l'hydroxychloroquine et utilisation therapeutique

Country Status (2)

Country Link
FR (1) FR3076711B1 (fr)
WO (1) WO2019138203A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317482A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 氯喹及其衍生物在制备改善鼻咽癌预后药物中的应用
CN115317483A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 氯喹及其衍生物在制备PGCCs抑制剂中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法

Also Published As

Publication number Publication date
FR3076711A1 (fr) 2019-07-19
WO2019138203A1 (fr) 2019-07-18

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA42279A (fr) Compositions comprenant une souche bactérienne de blautia hydrogenotrophica pour l'utilisation pour la prevention ou le traitement de la diarrhee ou la constipation
WO2019032662A8 (fr) Agents de liaison à clec9a et utilisations associées
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
MA52971A (fr) Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
FR3076711B1 (fr) Composition comprenant l'hydroxychloroquine et utilisation therapeutique
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
FR3073398B1 (fr) Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire
MA55274A (fr) Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
EA202190755A1 (ru) Агенты для терапии и диагностики рака

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190719

RM Correction of a material error

Effective date: 20191127

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6